Mostrar el registro sencillo del ítem

dc.contributor.authorMora, José R.
dc.contributor.authorCuesta, Sebastián A
dc.contributor.authorBelhassan, Assia
dc.contributor.authorSalgado Morán, Guillermo
dc.contributor.authorLakhlifi, Tahar
dc.contributor.authorBouachrine, Mohammed
dc.contributor.authorPeña F., Carlos
dc.contributor.authorGerli C., Lorena
dc.contributor.authorMendoza-Huízar, Luís Humberto
dc.date.accessioned2021-11-03T16:07:45Z
dc.date.available2021-11-03T16:07:45Z
dc.date.issued2022-08-15
dc.identifier10.33263/BRIAC124.55915600
dc.identifier.issn20695837
dc.identifier.urihttps://hdl.handle.net/20.500.12728/9671
dc.description.abstractIn this study, Crocin, Digitoxigenin, Beta-Eudesmol, and Favipiravir were docked in the active site of SARS-CoV-2 main protease (PDB code: 6LU7). The docking study was followed by Molecular Dynamics simulation. The result indicates that Crocin and Digitoxigenin are the structures with the best affinity in the studied enzyme's binding site. Still, Molecular Dynamics simulation showed that Digitoxigenin is the molecule that fits better in the active site of the main protease. Therefore, this molecule could have a more potent antiviral treatment of COVID-19 than the other three studied compounds.es_ES
dc.language.isoenes_ES
dc.publisherAMG Transcend Associationes_ES
dc.subjectBeta-Eudesmoles_ES
dc.subjectCrocines_ES
dc.subjectDigitoxigenines_ES
dc.subjectFavipiravires_ES
dc.subjectSARS-CoV-2es_ES
dc.titleMolecular docking and molecular dynamics studies of sars-cov-2 inhibitors: Crocin, digitoxigenin, beta-eudesmol and favipiravir: Comparative studyes_ES
dc.typeArticlees_ES


Ficheros en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem